Division of Miraca Holdings Inc.
Latest From SRL Inc.
Nippon Shinyaku obtains rights to sell Dravet and Lennox-Gastaut syndrome drug Fintepla in its home market. Sun Pharma increases its ownership stake in Russia’s PJSC Biosintez.
Despite the early-90s failure of its first product, an anti-sepsis monoclonal antibody, Xoma Corp. has persisted in developing pharmaceuticals for endotoxin-related disorders. The firm has no intention of letting past failings, like the lack of a rapid diagnostic, sink it twice. So it's doing deals with diagnostics companies, and talking up recent research about endotoxins.
- Contract Research, Toxicology Testing-CRO
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Miraca Holdings Inc.
- Senior Management
K. Fujita, MD, PhD, Pres. & CEO
K. Kubota, Mgr., Product Planning
H. Tukada, MD, PhD, Dir., R&D
- Contact Info
Phone: (81) 3 3344 6511
Yasudakasai Tachikawa Bldg.